Assessment of the outcomes associated with periprocedural anticoagulation management in children with acute lymphoblastic leukemia

J Pediatr. 2014 May;164(5):1201-7. doi: 10.1016/j.jpeds.2014.01.031. Epub 2014 Feb 25.

Abstract

Objective: To report the outcomes of an institutional protocol for periprocedural anticoagulant (AC) management in children with acute lymphoblastic leukemia (ALL).

Study design: Children being treated for ALL who received full-dose (therapeutic) anticoagulation before undergoing at least 1 lumbar puncture (LP) were included in this retrospective cohort study. The main outcome was the risk of traumatic LP; exploratory analysis included the risks of symptomatic spinal hematoma and progression/recurrence of the thrombotic event. Analyses were conducted using logistic regression analysis with a generalized estimating equation approach.

Results: Twenty-two children with ALL receiving an AC underwent a total of 396 LPs. Although traumatic LP was associated with full-dose AC therapy in univariable analysis, a multiple logistic regression model controlling for other risk factors for traumatic LP showed that AC therapy was not significantly associated with the risk of traumatic LP when the ACs were held as per the institutional protocol. No patient developed symptomatic spinal hematoma. Exploratory analysis revealed that AC dose, a likely marker of thrombus burden, was significantly associated with progression/recurrence of the thrombotic event in univariable analysis.

Conclusion: In our cohort, recent AC therapy was not statistically associated with an increased risk of bleeding after LP when following a specific protocol for periprocedural AC management. The risk associated with the progression/recurrence of thromboembolic events requires further evaluation.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use
  • Child
  • Child, Preschool
  • Clinical Protocols
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Hematoma / chemically induced*
  • Hematoma / prevention & control
  • Heparin / adverse effects
  • Heparin / therapeutic use
  • Heparin, Low-Molecular-Weight / adverse effects
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Infant
  • Logistic Models
  • Male
  • Multivariate Analysis
  • Postoperative Complications / chemically induced*
  • Postoperative Complications / prevention & control
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • Preoperative Care / methods
  • Recurrence
  • Retrospective Studies
  • Risk Factors
  • Spinal Diseases / chemically induced*
  • Spinal Diseases / prevention & control
  • Spinal Puncture*
  • Thrombosis / drug therapy*
  • Thrombosis / etiology
  • Thrombosis / prevention & control
  • Treatment Outcome

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Heparin